Cingulate Inc. (CINGW)
| Market Cap | 59.34M +250.2% |
| Revenue (ttm) | n/a |
| Net Income | -27.91M |
| EPS | -4.24 |
| Shares Out | 13.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,558 |
| Open | 0.0350 |
| Previous Close | 0.0299 |
| Day's Range | 0.0161 - 0.0369 |
| 52-Week Range | 0.0154 - 0.1750 |
| Beta | -0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About CINGW
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical... [Read more]
News
Cingulate price target lowered to $10 from $14 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $10 from $14 and keeps a Buy rating on the shares, citing Q1 updates for the…
Cingulate Proxy statement: Proxy filing
Cingulate filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to devel...
Cingulate Earnings release: Q1 2026
Cingulate released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cingulate Quarterly report: Q1 2026
Cingulate has published its Q1 2026 quarterly earnings report on May 14, 2026.
Six new option listings on April 22nd
New option listings for April 22nd include SPDR Bridgewater All Weather ETF (ALLW), Cingulate Inc (CING), Tema ETF Trust (NASA), Eagle Nuclear Energy Corp (NUCL), Versigent PLC (VGNT), and Xanadu…
Cingulate files to sell 4.21M shares of common stock for holders
17:27 EDT Cingulate (CING) files to sell 4.21M shares of common stock for holders
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on April 14, 2026, providing details about a securities offering with the SEC.
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues t...
Cingulate Slides: Corporate presentation
Cingulate has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on March 23, 2026, providing details about a securities offering with the SEC.
Cingulate price target lowered to $14 from $16 at Roth Capital
Roth Capital lowered the firm’s price target on Cingulate (CING) to $14 from $16 and keeps a Buy rating on the shares. The company’s new drug application for CTx-1301 in…
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on March 20, 2026, providing details about a securities offering with the SEC.
Cingulate files to sell 3.5M shares of common stock for holders
07:40 EDT Cingulate (CING) files to sell 3.5M shares of common stock for holders
Cingulate announces U.S. patent notice of allowance
On Tuesday, March 17th, 2026, the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering Cingulate’s (CING) lead ADHD candidate, CTx-1301, indicating ...
Cingulate reports Q4 net loss $6.3M vs. $6.2M last year
Cingulate (CING) CEO Shane Schaffer stated, “Cingulate delivered on key inflection points throughout 2025 and this continues into 2026. Cingulate is proud to announce that CTx-1301 has strengthened it...
Cingulate sees cash runway into late 4Q26
As of December 31, 2025, Cingulate (CING) had approximately $11.0 million in cash and cash equivalents, a $1.3 million decrease from December 31, 2024. The Company expects current cash on…
Cingulate Proxy statement: Proxy Filing
Cingulate filed a proxy statement on March 18, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate Earnings release: Q4 2025
Cingulate released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Cingulate Annual report: Q4 2025
Cingulate has published its Q4 2025 annual report on March 18, 2026.
Why did Cingulate stock skyrocket today?
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Table...
Cingulate Proxy statement: Proxy Filing
Cingulate filed a proxy statement on March 2, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate Proxy statement: Proxy Filing
Cingulate filed a proxy statement on February 18, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate files $200M mixed securities shelf
17:10 EST Cingulate (CING) files $200M mixed securities shelf
Cingulate Registration statement: Registration Filing
Cingulate filed a registration statement on January 12, 2026, providing details about a securities offering with the SEC.